|
Sep 6
|
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
|
|
Aug 27
|
Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...
|
|
Jul 30
|
Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024
|
|
Jul 30
|
Undiscovered Gems In The United States For July 2024
|
|
Jul 23
|
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
|
|
Jul 9
|
Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
|
|
Jul 8
|
Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties
|
|
Jul 8
|
Ligand to buy Apeiron; Roche reports another TIGIT setback
|
|
Jul 8
|
Ligand to Acquire APEIRON Biologics AG for $100 Million
|
|
Jun 24
|
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
|
|
Jun 19
|
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
|
|
Jun 19
|
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
|
|
Jun 19
|
The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable
|
|
Jun 18
|
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
|
|
Jun 14
|
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
|
|
Jun 14
|
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
|
|
Jun 14
|
What Makes Ligand (LGND) a New Strong Buy Stock
|
|
May 23
|
Ligand to Participate in Upcoming Investor Conferences
|
|
May 21
|
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
|
|
May 21
|
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
|